Healthcare > Pharmaceuticals & Biotechnology
•2432 stocks
•
Total Market Cap: Loading...
Price Performance Heatmap
5Y Price (Market Cap Weighted)
All Stocks (2432)
| Company | Market Cap | Price |
|---|---|---|
|
APRE
Aprea Therapeutics, Inc.
APRE is an oncology-focused biotech developing cancer therapies, namely DDR inhibitors, which aligns with Biotech - Oncology.
|
$5.18M |
$0.90
+0.12%
|
|
CELZ
Creative Medical Technology Holdings, Inc.
CELZ develops autologous/allogeneic cell therapies (ImmCelz and AlloStem), a core cell therapy business.
|
$5.16M |
$2.02
+6.32%
|
|
CPHI
China Pharma Holdings, Inc.
Core product: generic drugs manufacturing (Helpson's portfolio in PRC).
|
$5.07M |
$1.55
-0.26%
|
|
CLDI
Calidi Biotherapeutics, Inc.
Calidi Biotherapeutics directly develops cancer therapies (oncolytic virus platforms) targeting oncology indications.
|
$4.92M |
$1.02
-1.92%
|
|
PAVM
PAVmed Inc.
PAVmed's biopharma expansion targets oncology assets, aligning with Biotech - Oncology.
|
$4.81M |
$6.45
-26.29%
|
|
KALA
KALA BIO, Inc.
KPI-012 is a mesenchymal stem cell secretome (MSC-S) therapy, aligning with Biotech - Cell Therapy.
|
$4.74M |
$0.67
+10.80%
|
|
CYCN
Cyclerion Therapeutics, Inc.
Cyclerion is centered on neuropsychiatric drug development, specifically an individualized therapy for Treatment Resistant Depression (TRD).
|
$4.54M |
$1.41
+3.31%
|
|
POAI
Predictive Oncology Inc.
Biotech - Oncology focus via proprietary biobank, wet-lab validation, and AI-enabled oncology drug discovery.
|
$4.32M |
$5.94
-0.17%
|
|
TTNP
Titan Pharmaceuticals, Inc.
Titan's core ProNeura technology is a long-acting drug delivery platform used for subdermal implants.
|
$4.21M |
$4.61
|
|
ACXP
Acurx Pharmaceuticals, Inc.
Lead product ibezapolstat is an oral small-molecule antibiotic for CDI, aligning with the 'Oral Small Molecule Therapeutics' investable theme.
|
$4.20M |
$2.69
-0.19%
|
|
PPCB
Propanc Biopharma, Inc.
Propanc Biopharma is a development-stage biotechnology company focusing on oncology therapies, making PRP its core candidate.
|
$4.01M |
$0.31
-10.90%
|
|
SONN
Sonnet BioTherapeutics Holdings, Inc.
Sonnet's core pipeline is oncology-focused immunotherapies (e.g., SON-1010 IL-12) leveraging the FHAB platform.
|
$3.99M |
$1.28
+1.98%
|
|
BCLI
Brainstorm Cell Therapeutics Inc.
NurOwn is a proprietary autologous cell therapy platform developed by Brainstorm for ALS and related neurodegenerative indications, directly produced and administered by the company.
|
$3.82M |
$0.59
|
|
OGEN
Oragenics, Inc.
ONP-002 uses a proprietary intranasal drug-delivery platform (powder formulation + breath-propelled device).
|
$3.77M |
$0.95
+2.56%
|
|
PHGE
BiomX Inc.
BiomX leverages a drug delivery platform (BOLT) to rapidly assemble phage cocktails and targeted therapies.
|
$3.74M |
$2.60
-0.38%
|
|
LADX
LadRx Corporation
LadRx is a biotechnology company focused on oncology drug development.
|
$3.70M |
$0.11
|
|
AIM
AIM ImmunoTech Inc.
Ampligen is AIM ImmunoTech's flagship oncology/immunotherapy platform and is being developed with cancer indications (pancreatic and ovarian cancer) in combination with checkpoint inhibitors.
|
$3.63M |
$1.34
|
|
SILO
Silo Pharma, Inc.
Drug Delivery Platforms directly describes Silo's intranasal and implantable drug delivery technologies (SPC-15, SPC-14, SP-26).
|
$3.55M |
$0.38
-1.00%
|
|
LYRA
Lyra Therapeutics, Inc.
XTreo drug-delivery platform is Lyra's core product, enabling six months of localized drug therapy via in-office implant (LYR-210).
|
$3.27M |
$1.98
+1.54%
|
|
GOVX
GeoVax Labs, Inc.
GeoVax directly develops and manufactures vaccines using its MVA platform for infectious diseases (Mpox/smallpox and COVID-19 programs).
|
$3.03M |
$2.97
+4.21%
|
|
BZYR
Burzynski Research Institute, Inc.
Company focuses on oncology therapeutics in biotech R&D.
|
$3.02M |
$0.04
|
|
HCWB
HCW Biologics Inc.
HCWB's lead programs target oncology through novel immunotherapies, aligning with Biotech - Oncology.
|
$2.97M |
$1.36
+19.30%
|
|
BICX
BioCorRx Inc.
BioCorRx is actively commercializing Lucemyra, an FDA-approved oral small molecule therapeutic for opioid withdrawal, expanding direct product sales.
|
$2.65M |
$0.40
|
|
JAGX
Jaguar Health, Inc.
Jaguar Health focuses on crofelemer-based therapies delivered orally, aligning with the Oral Small Molecule Therapeutics category.
|
$2.54M |
$1.18
+3.98%
|
|
CARM
Carisma Therapeutics, Inc.
CAR-Macrophage platform is a cell-therapy technology, directly representing Carisma's core product category.
|
$2.33M |
$0.15
+196.92%
|
|
CLSD
Clearside Biomedical, Inc.
Clearside's core offering is a drug delivery platform enabling suprachoroidal (eye) delivery and extended-release formulations.
|
$2.15M |
$0.43
+4.90%
|
|
AAGH
America Great Health
Focus on peptide/protein therapeutics as a core research and therapeutic development area.
|
$2.12M |
$0.00
|
|
YBGJ
Yubo International Biotech Limited
Endometrial stem cell research and potential cell therapies (core biotech focus).
|
$2.11M |
$0.01
|
|
CANF
Can-Fite BioPharma Ltd.
Company focuses on orally bioavailable small molecule therapeutics targeting A3AR, including Piclidenoson and Namodenoson.
|
$1.99M |
$4.00
-6.54%
|
|
SHPH
Shuttle Pharmaceuticals Holdings, Inc.
Company is a oncology-focused biotech developing radiation sensitizers and HDAC inhibitor therapeutics, with lead assets in Phase 2/preclinical stages.
|
$1.98M |
$1.79
-2.97%
|
|
BIOE
Bio Essence Corporation
Provides outsourced contract manufacturing (OEM) services for health-related products.
|
$1.94M |
$0.05
|
|
APVO
Aptevo Therapeutics Inc.
APVO is a oncology-focused biotech developing novel immunotherapies, including mipletamig and other pipelines targeting cancer.
|
$1.73M |
$9.35
+3.49%
|
|
ELAB
PMGC Holdings Inc.
Contract Research Organizations (CRO)-like R&D capabilities through PMGC Research Inc. for biotech development.
|
$1.63M |
$3.35
-13.12%
|
|
REVB
Revelation Biosciences, Inc.
Core product focus on modulating innate immunity using the Gemini platform, aligning with Immunology Therapeutics.
|
$1.61M |
$0.95
+6.12%
|
|
ENVB
Enveric Biosciences, Inc.
Enveric is focused on neuropsychiatric drug development with a lead program targeting neuroplasticity-based therapies.
|
$1.45M |
$5.21
-2.71%
|
|
SXTC
China SXT Pharmaceuticals, Inc.
SXTC manufactures TCMP products and operates GMP-compliant production lines, consistent with a contract manufacturing organization (CMO) model.
|
$1.31M |
$0.09
-11.59%
|
|
GRTX
Galera Therapeutics, Inc.
Company directly develops oncology therapeutics, including its NOS pan-inhibitor and SOD mimetics for cancer indications.
|
$1.31M |
$0.02
|
|
BIAF
bioAffinity Technologies, Inc.
The business focuses on oncology diagnostics (early detection of lung cancer).
|
$1.30M |
$1.35
-4.93%
|
Showing page 24 of 25 (2432 total stocks)
Loading company comparison...
Loading industry trends...
Loading research report...
